Molecular Mechanism and Clinical Optimization of Isotretinoin in the Treatment of Acne
DOI:
https://doi.org/10.61173/tf6xrb63Keywords:
Isotretinoin, acne, p53, dosage strategy, combination therapyAbstract
Acne is a very common chronic inflammatory skin disease that can cause permanent scarring and psychological problems. Oral isotretinoin is the first choice for severe and persistent acne. To this day, the exact molecular mechanism of action is not well-known, and thus it has not been applied in clinical practice. With the latest research, this paper will systematically explain the current molecular mechanisms of isotretinoin in the treatment of acne and evaluate its clinical effect and improvement direction. Isotretinoin has some anti-inflammatory and normalising effects on the secretion of the outer layer, changes in cell division of keratinocytes, etc. Based on the above clinical studies, the usual dose of isotretinoin has good clearance in severe acne; a low-dose regimen can also be used to treat mild acne and rosacea. Combination of Laser and Phototherapy Treatment. Generally speaking, the amount of dry skin and mucous membranes after a single dose varies among individuals. Based on current research, it has not been found that isotretinoin causes depression or inflammatory bowel disease. In the future, through nanomedicine formulations, molecular modification and combination therapy, it is expected that isotretinoin will be more effective and safer.
References
[1] TAN J,BOYAL S,DESAI K,et al.Oral Isotretinoin:new developments relevant to clinical practice[J].Dermatologic Clinics.2016,34(2):175-184.
[2] LANDIS M N.Optimizing isotretinoin treatment of acne:update on current recommendations for monitoring,dosin g,safety,adverse effects,compliance,and outcomes[J].American Jornal of Clinical Dermatology,2020,21(3):411-419.
[3] CHU S,MICHELLEL L,EKELEM C,et al.Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions[J]. Archives of Dermatological Research,2021,313(6):391-430.
[4] MOHSIN N,HERNANDEZ L E,MARTIN M R,et al.Acne treatment review and future perspectives[J].Dermatologic Therapy,2022,35(9):e15719.
[5] MELNIK B C.Acne transcriptomics: fundamentals of acne pathogenesis and isotretinoin treatment[J]. Cells,2023,12(22):2600.
[6] WIEGAND U W,CHOU R C.Pharmacokinetics of oral isotretinoin[J].Journal of the American Academy of Dermatology,1998,39(2 Pt 3):S8-S12.
[7] PAICHITROJJANA A,PAICHITROJJANA A.Oral isotretinoin and its uses in dermatology: a review[J].Drug Design,Development and Therapy,2023,17:2573-2591.
[8] MELNIK B C.Overexpression of p53 explains isotretinoin's teratogenicity[J].Experimental Dermatology,2018,27(1):91-93.
[9] HOSSEINPOUR P,GHOLAMABBAS G,PEZESHKIAN F,et al. Practice and attitude of general practitioners towards initiating isotretinoin for acne vulgaris in Fars province,Iran: cross-sectional study[J].BMC Primary Care,2024,25(1):27.
[10] TAN T H,HALLETT R,YESUDIAN P D.Efficacy and relapse rates of different isotretinoin dosages in treating acne vulgaris:a systemic review[J].Clinical Medicine,2016,16(Suppl 3):s34.
[11] KING A,TAN M G,KIRSHEN C,et al.Low-dose isotretinoin for the management of rosacea:a systematic review and metaanalysis[J].Journal of the European Academy of Dermatology and Venereology,2025,39(4):785-792.
[12] HE S X,WANG Y,WANG J,et al.Isotretinoin combined laser/light-based treatments versus isotretinoin alone for the treatment of acne vulgaris: a meta-analysis[J].2024.
[13] XU B,WU J,XU Z,et al.Optimized combination: isotretinoin in conjunction with oral tranexamic acid for the treatment of moderate to severe acne vulgaris—a randomized,doubleblind,placebo-controlled trial[J].Journal of the American Academy of Dermatology,2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 by the authors.

This work is licensed under a Creative Commons Attribution 4.0 International License.
